CYP2B6 and neuroblastoma: The overall response rate was found to be associated with age categorized as younger and older than 1.5 years, and a trend was also observed toward significance with sex; however, neither the CYP2B6 or CYP2C19 haplotypes nor genotype-based phenotypes had an influence on therapeutic outcomes in neuroblastoma patients.